149 related articles for article (PubMed ID: 16546992)
1. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers.
Komatsu M; Hiyama K; Tanimoto K; Yunokawa M; Otani K; Ohtaki M; Hiyama E; Kigawa J; Ohwada M; Suzuki M; Nagai N; Kudo Y; Nishiyama M
Mol Cancer Ther; 2006 Mar; 5(3):767-75. PubMed ID: 16546992
[TBL] [Abstract][Full Text] [Related]
2. Selection of a novel drug-response predictor in esophageal cancer: a novel screening method using microarray and identification of IFITM1 as a potent marker gene of CDDP response.
Fumoto S; Shimokuni T; Tanimoto K; Hiyama K; Otani K; Ohtaki M; Hihara J; Yoshida K; Hiyama E; Noguchi T; Nishiyama M
Int J Oncol; 2008 Feb; 32(2):413-23. PubMed ID: 18202764
[TBL] [Abstract][Full Text] [Related]
3. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
Steffensen KD; Smoter M; Waldstrøm M; Grala B; Bodnar L; Stec R; Szczylik C; Jakobsen A
Int J Oncol; 2014 May; 44(5):1736-44. PubMed ID: 24585004
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
[TBL] [Abstract][Full Text] [Related]
5. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
Hartmann LC; Lu KH; Linette GP; Cliby WA; Kalli KR; Gershenson D; Bast RC; Stec J; Iartchouk N; Smith DI; Ross JS; Hoersch S; Shridhar V; Lillie J; Kaufmann SH; Clark EA; Damokosh AI
Clin Cancer Res; 2005 Mar; 11(6):2149-55. PubMed ID: 15788660
[TBL] [Abstract][Full Text] [Related]
7. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA let-7a: a potential marker for selection of paclitaxel in ovarian cancer management.
Lu L; Schwartz P; Scarampi L; Rutherford T; Canuto EM; Yu H; Katsaros D
Gynecol Oncol; 2011 Aug; 122(2):366-71. PubMed ID: 21571355
[TBL] [Abstract][Full Text] [Related]
9. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
10. Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer.
Han Y; Huang H; Xiao Z; Zhang W; Cao Y; Qu L; Shou C
PLoS One; 2012; 7(12):e52745. PubMed ID: 23300757
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer.
Kamazawa S; Kigawa J; Kanamori Y; Itamochi H; Sato S; Iba T; Terakawa N
Gynecol Oncol; 2002 Aug; 86(2):171-6. PubMed ID: 12144824
[TBL] [Abstract][Full Text] [Related]
12. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.
Bardella C; Dettori D; Olivero M; Coltella N; Mazzone M; Di Renzo MF
Clin Cancer Res; 2007 Apr; 13(7):2191-8. PubMed ID: 17404103
[TBL] [Abstract][Full Text] [Related]
14. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
15. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
[TBL] [Abstract][Full Text] [Related]
16. Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study.
Miglietta L; Amoroso D; Bruzzone M; Granetto C; Catsafados E; Mammoliti S; Guarneri D; Pedulla F; Foglia G; Ragni N; Martini MC; Brema F; Addamo G; Moraglio L; Pastorino G; Boccardo F
Oncology; 1997; 54(2):102-7. PubMed ID: 9075779
[TBL] [Abstract][Full Text] [Related]
17. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
Muñoz-Galván S; Felipe-Abrio B; García-Carrasco M; Domínguez-Piñol J; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sánchez A; Navas LE; Otero-Albiol D; Marin JJ; Jiménez-García MP; García-Heredia JM; Quiroga AG; Estevez-Garcia P; Carnero A
J Exp Clin Cancer Res; 2019 Jun; 38(1):234. PubMed ID: 31159852
[TBL] [Abstract][Full Text] [Related]
18. [Comparative clinical appraisal of the effectiveness and tolerability of paclitaxel-LANCE and taxol in combination chemotherapy for recurrences and platinum-refractory ovarian carcinoma].
Gershanovich ML; Makhnova EV; Livshits ME; Gulo EI
Vopr Onkol; 2004; 50(6):716-9. PubMed ID: 15755070
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitivity prediction in esophageal squamous cell carcinoma: novel marker genes and efficacy-prediction formulae using their expression data.
Shimokuni T; Tanimoto K; Hiyama K; Otani K; Ohtaki M; Hihara J; Yoshida K; Noguchi T; Kawahara K; Natsugoe S; Aikou T; Okazaki Y; Hayashizaki Y; Sato Y; Todo S; Hiyama E; Nishiyama M
Int J Oncol; 2006 May; 28(5):1153-62. PubMed ID: 16596231
[TBL] [Abstract][Full Text] [Related]
20. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
